Filtered By:
Condition: Hemorrhagic Stroke
Cancer: Primary CNS Lymphoma
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Clinical utility of serum glial fibrillary acidic protein in glial neoplasm
CONCLUSION: Increasing serum GFAP levels in the preoperative period correlate with higher tumor grade, especially grade III and grade IV tumors. The serum GFAP levels showed relation to tumor volume, both before and after surgery.PMID:36761257 | PMC:PMC9899464 | DOI:10.25259/SNI_889_2022
Source: Surgical Neurology International - February 10, 2023 Category: Neurosurgery Authors: Nidhi Yadav Keshav Mishra Anil Kumar B C Daljit Singh Manju Subberwal Source Type: research
